Literature DB >> 23508516

Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria.

Evelyne Bareck1, Ahmed Ba-Ssalamah, Thomas Brodowicz, Wolfgang Eisterer, Michael Häfner, Christoph Högenauer, Ulrike Kastner, Thomas Kühr, Friedrich Längle, Bernadette Liegl-Atzwanger, Sebastian F Schoppmann, Gerlig Widmann, Fritz Wrba, Johannes Zacherl, Ferdinand Ploner.   

Abstract

Optimal treatment for patients suffering from gastrointestinal stromal tumors (GIST) is based on an interdisciplinary treatment approach. Austrian representatives of Medical and Surgical Oncology, Pathology, Radiology, Nuclear Medicine, Gastroenterology, and Laboratory Medicine issued this manuscript on a consensual base within the context of currently available and published literature. This paper contains guidelines and recommendations for diagnosis, therapy, and follow-up of GIST patients in Austria.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23508516     DOI： 10.1007/s10354-013-0187-3

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  121 in total

1.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

Review 2.  Laparoscopic treatment of gastric GIST: report of 21 cases and literature's review.

Authors:  Fausto Catena; Monica Di Battista; Pietro Fusaroli; Luca Ansaloni; Valerio Di Scioscio; Donatella Santini; Maria Pantaleo; Guido Biasco; Giancarlo Caletti; Antonio Pinna
Journal:  J Gastrointest Surg       Date:  2007-11-27       Impact factor: 3.452

3.  Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.

Authors:  W Ruka; P Rutkowski; A Szawłowski; Z Nowecki; M Debiec-Rychter; U Grzesiakowska; W Dziewirski; J A Siedlecki; W Michej
Journal:  Eur J Surg Oncol       Date:  2008-03-04       Impact factor: 4.424

4.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Authors:  B Liegl; I Kepten; C Le; M Zhu; G D Demetri; M C Heinrich; C D M Fletcher; C L Corless; J A Fletcher
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

5.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

6.  Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.

Authors:  Eric P Kleinbaum; Alexander J F Lazar; Elena Tamborini; John C Mcauliffe; Pamela B Sylvestre; Thomas D Sunnenberg; Louise Strong; Lei L Chen; Haesun Choi; Robert S Benjamin; Wei Zhang; Jonathan C Trent
Journal:  Int J Cancer       Date:  2008-02-01       Impact factor: 7.396

Review 7.  Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.

Authors:  Eva Wardelmann; Reinhard Büttner; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus
Journal:  Virchows Arch       Date:  2007-08-14       Impact factor: 4.064

8.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

Authors:  Jean-Yves Blay; Axel Le Cesne; Isabelle Ray-Coquard; Binh Bui; Florence Duffaud; Catherine Delbaldo; Antoine Adenis; Patrice Viens; Maria Rios; Emmanuelle Bompas; Didier Cupissol; Cecile Guillemet; Pierre Kerbrat; Jérome Fayette; Sylvie Chabaud; Patrice Berthaud; David Perol
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

9.  Gastrointestinal stromal tumors--value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas.

Authors:  M Miettinen; M Virolainen
Journal:  Am J Surg Pathol       Date:  1995-02       Impact factor: 6.394

10.  Single center experience of laparoscopic vs. open resection for gastrointestinal stromal tumors of the stomach.

Authors:  V Pitsinis; A Z Khan; I Cranshaw; W H Allum
Journal:  Hepatogastroenterology       Date:  2007-03
View more
  6 in total

Review 1.  [Gastrointestinal stromal tumors: diagnostics and therapy].

Authors:  V Fendrich; D K Bartsch
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

2.  Expression of L1 protein correlates with cluster of differentiation 24 and integrin β1 expression in gastrointestinal stromal tumors.

Authors:  Yue DU; Haihong Zhang; Zhongmin Jiang; Guowei Huang; Wenli Lu; Hesheng Wang
Journal:  Oncol Lett       Date:  2015-04-02       Impact factor: 2.967

3.  Expression profile of microRNAs in gastrointestinal stromal tumors revealed by high throughput quantitative RT-PCR microarray.

Authors:  Han-Xing Tong; Yu-Hong Zhou; Ying-Yong Hou; Yong Zhang; Yuan Huang; Bin Xie; Jiong-Yuan Wang; Quan Jiang; Jun-Yi He; Ye-Bo Shao; Wu-Mei Han; Ruo-Ying Tan; Jun Zhu; Wei-Qi Lu
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

4.  IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach.

Authors:  Josef Singer; Erika Jensen-Jarolim
Journal:  J Carcinog Mutagen       Date:  2014-05-31

5.  Laparoscopic resection of large gastric gastrointestinal stromal tumours.

Authors:  Sebastian Smolarek; Eoghan Pomeroy; Fiona Kinnarney; Mayilone Arumugasamy
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2015-12-16       Impact factor: 1.195

6.  Large cystic-based gastrointestinal stromal tumor: A case report.

Authors:  Xinqi Chen; Huizeng Lv; Wenhai Zhang; Jie Cao
Journal:  Oncol Lett       Date:  2014-01-15       Impact factor: 2.967
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.